Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
89 studies found for:    Alpha-1 Antitrypsin Deficiency
Show Display Options
Rank Status Study
21 Completed Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients
Conditions: Chronic Obstructive Pulmonary Disease;   Alpha-1-antitrypsin-deficiency
Intervention: Procedure: exercise training
22 Completed
Has Results
Pharmacokinetic Study of ARALAST (Human Alpha1- PI)
Condition: Alpha 1-Antitrypsin Deficiency
Interventions: Biological: Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor;   Biological: Dose of 60 mg/kg alpha1-proteinase inhibitor
23 Completed
Has Results
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Biological: Alpha1-Proteinase Inhibitor
24 Recruiting Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency
Condition: Alpha1-Antitrypsin Deficiency
Intervention: Biological: Alpha-1 MP
25 Terminated Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention:
26 Completed Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Drug: Aerosolized, Recombinant Alpha 1-Antitrypsin
27 Recruiting Alpha-1 Foundation Research Registry
Condition: Alpha 1-Antitrypsin Deficiency
Intervention:
28 Completed Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Drug: Kamada-API
29 Completed Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Condition: Alpha 1 Antitrypsin Deficiency
Intervention: Drug: Alpha-1 Antitrypsin (human)
30 Completed
Has Results
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Drug: alpha-1 proteinase inhibitor (human)
31 Active, not recruiting A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Condition: Antitrypsin Deficiency Liver Disease
Interventions: Drug: ALN-AAT;   Drug: Sterile Normal Saline (0.9% NaCl)
32 Completed
Has Results
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
Conditions: Emphysema;   Alpha 1-proteinase Inhibitor Deficiency
Intervention: Biological: Alpha1- proteinase inhibitor [human]
33 Completed
Has Results
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
Conditions: Alpha1-proteinase Inhibitor Deficiency;   Emphysema
Interventions: Biological: Alpha1-proteinase inhibitor;   Other: Placebo
34 Unknown  Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency
Conditions: Alpha-1-Antitrypsin Deficiency;   Chronic Obstructive Lung Disease;   Emphysema
Intervention: Device: Lung Volume Reduction Coil (PneumrX Inc.)
35 Completed
Has Results
Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Condition: Alpha 1-Antitrypsin Deficiency
Interventions: Drug: Alpha1-Proteinase Inhibitor (Human);   Drug: Albumin (Human) 20%, United States Pharmacopeia (USP)
36 Unknown  Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema
Conditions: Alpha 1-Antitrypsin Deficiency;   Emphysema
Intervention:
37 Withdrawn Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Condition: Alpha-1 Antitrypsin Deficiency
Intervention: Drug: ARC-AAT Injection
38 Completed Phase II, Safety and ELF Study of "Kamada-API for Inhalation"
Condition: Alpha-1 Antitrypsin Deficiency
Interventions: Biological: Kamada-API for Inhalation, 80mg;   Drug: Placebo;   Biological: Kamada-API for Inhalation, 160mg
39 Active, not recruiting Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Genetic: rAAV2-CB-hAAT Gene Vector
40 Recruiting Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
Condition: Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions: Biological: Alpha1-proteinase inhibitor (human), modified process (Alpha-1 MP);   Other: 0.9% Sodium Chloride for Injection, USP

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.